Hidradenitis SuppurativaHS PROGRESSNCT04115566
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
An observational study of Hidradenitis Suppurativa, run by University of California, San Francisco at 1 site in United States.
Trial summary
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. Read more about this study
- Who is it for?
- Ages 10 years and older
- Conditions the study is for
- Hidradenitis Suppurativa
- How many people
- 3,000 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2020to 1 May 2035
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 years and older
- All sexes
- Child, Adult, Older adult
Study population: HS Patients
Who may be able to join
- Male or female ≥ 10 years of age
- Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Who cannot join
- 1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of California San Francisco
San Francisco, California, 94115
Haley B Naik, MD, MHSc, FAAD
About this study
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.
- Conditions
- Hidradenitis Suppurativa
- Medical subject headings
- Hidradenitis Suppurativa
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Objective
The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.
Measured: 2019-2035
Secondary outcomes (1)
Secondary Objective
Secondary aims include correlating alterations in clinical and biological characteristics with disease status, and identifying genetic variants that predict disease progression or response to therapy.
Measured: 2019-2035
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2019
- Study start1 Aug 2020
- Primary completion1 May 2035 (estimated)
- Study completion1 May 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hidradenitis SuppurativaStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Collaborators
- UCB Pharma
- Responsible party
- Sponsor
- Investigators
- Haley B Naik, MD, MHSc, FAAD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04115566
- Sponsor's protocol ID
- 18-27002
- Acronym
- HS PROGRESS
- Status last verified
- Apr 2026
- First submitted
- 18 Sep 2019
- Last updated
- 29 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No